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ABSTRACT
Aims Increased nicotinemetabolism during pregnancy could explain why nicotine replacement therapy (NRT) appears to
be less effective on smoking cessation in pregnancy than in non-pregnant smokers, but little is known about nicotine me-
tabolism across pregnancy. This studywas conducted to determinewhen changes in nicotinemetabolism occur during preg-
nancy and to describe the magnitude of these changes. Design Longitudinal cohort study of pregnant smokers’ nicotine
metabolite ratio (NMR). Setting and Participants 101 pregnant smokers recruited from hospital antenatal clinics in
Nottingham, UKwere asked to provide saliva samples at 8–14 weeks (n=98), 18–22 weeks (n=65), 32–36 weeks gesta-
tion (n=47), 4 weeks postpartum (n=44) and 12 weeks postpartum (n=47).Measurements Nicotine metabolite ratio
(NMR) was measured using the ratio of cotinine to its primary metabolite trans-3’-hydroxycotinine. Multi-level modelling
was used to detect any overall difference in NMR between time points. The 12 week postpartum NMRwas compared with
the NMRs collected antenatally and 4weeks postpartum. Findings NMR changed over time (p=0.0006). Comparedwith
NMRat 12weeks postpartum, NMRwas signiﬁcantly higher at 18–22weeks (26%higher, 95%CI 12% to 38%) and 32–36
weeks (23% higher, 95% CI 9% to 35%). There was no signiﬁcant difference between the 8-14 weeks gestation or 4 weeks
postpartum NMR and 12 weeks postpartum. Conclusions Nicotine metabolism appears to be faster during pregnancy;
this faster metabolism is apparent from 18 to 22 weeks of pregnancy and appears to fall by 4 weeks after childbirth.
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INTRODUCTION
Smoking in pregnancy is associated strongly with adverse
pregnancy and birth outcomes [1]. Nicotine replacement
therapy (NRT) is often provided to assist pregnant women
to stop smoking, yet despite its effectiveness in non-
pregnant populations, NRT has not been found in random-
ized controlled trials to be effective in pregnancy, except
possibly in the short term [2,3]. A potential reason for this
may be that nicotine metabolism is increased during preg-
nancy [4–7]. It is possible that the dose of nicotine in NRT
may not be enough to reduce cigarette cravings adequately.
Currently, we do not know exactly when changes in
nicotine metabolism begin. Most studies have suggested
that change in nicotine metabolism occurs by the second
trimester of pregnancy, but little is known about nicotine
metabolism in the ﬁrst trimester and postpartum. No studies
have attempted to measure the rate of nicotine metabolism
from early pregnancy, throughout gestation and into the
postpartum. Using saliva samples to provide current mea-
surements of nicotinemetabolism, this study aims to address
the following: to (1) determine at what gestation changes in
nicotine metabolism occur; and (2) describe the magnitude
of changes in nicotine metabolism across pregnancy.
METHODS
This is a longitudinal cohort study measuring the nicotine
metabolism of pregnant and postpartum women who
smoke daily. Saliva samples were analysed to obtain their
nicotine metabolite ratio at ﬁve points; at recruitment
between 8 and 14weeks’ gestation with follow-up at 18–22,
32–36weeks’ gestation, and at 4 and 12weeks postpartum.
Participants were recruited from hospital antenatal
clinics in Nottingham, UK, between August 2013 and
October 2013, with follow-up completed by October 2014.
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Participants were included if they smoked one cigarette or
more per day, were aged 16years or over, had a singleton
pregnancy and self-reported being between 8 and 14weeks’
gestation. Participants were excluded if they self-reported
that they had consumed grapefruit within the last 24hours
[8], had liver or renal health problems or used medication
other than the following: iron supplementation, vitamin
supplements, folic acid and medications to treat asthma.
The researcher took written informed consent and
asked participants to provide a saliva sample using a sterile
Salivette swab, an exhaled carbon monoxide reading (CO)
and had their height and weight measured. They were also
asked to complete a short survey containing questions
about their age, education, employment status and nico-
tine dependence, measured by the Fagerström Test for
Nicotine Dependence (FTND) [9].
Participants were notiﬁed by telephone or text to alert
them that follow-up saliva kits were being posted to their
home, along with surveys containing questions about
nicotine dependence. Anyone who had stopped smoking
during the study was instructed to not provide a sample
while they were abstinent. In order to encourage response
rates, participants received a £5 high street shopping
voucher; this amount was increased to £20 for the ﬁnal
postpartum sample in order to improve return rates. The
study was given a favourable ethical opinion by East
Midlands, Nottingham 2 Research Ethics Committee.
Sample analysis
Samples were stored frozen at –20 degrees centigrade and
stored at Nottingham Health Science Biobank before being
sent by courier to ABS Laboratories Ltd, Welwyn Garden
City, UK for analysis. Assays were carried out on the saliva
to provide a measurement of cotinine and trans-3’-
hydroxycotinine. The use of saliva to measure nicotine me-
tabolites is a validated method of assessing exposure to
nicotine [10]. The samples were quantiﬁed by liquid
chromatography–tandemmass spectrometry (LC-MS/MS).
The LC-MS/MS method involved the addition of deuter-
ated internal standards for both analytes, addition of a pH7
buffer then liquid–liquid extraction using ethyl acetate
prior to hydrophilic liquid chromatography tandem mass
spectrometry using TurboIonspray in the positive ioniza-
tion mode using a CTC Agilent 1100 AB SCIEX API4000
LC-MS/MS system [11]. The assay range for both analytes
was 1–500ng/mL. Any over-range samples were diluted
and re-assayed. Precision was less than or equal to 10.3%
for cotinine and less than or equal to 8.2% for 3-hydroxy
cotinine; mean accuracy ranged from88.8 to 107% for co-
tinine and from 98.6 to 101% for 3’-hydroxycotinine. Once
analysis had taken place, samples were destroyed in
accordance with the Human Tissue Act, 2004.
Outcome measures
Nicotine metabolite ratio (NMR) was measured by using
the ratio of cotinine (COT) to its primary metabolite
trans-3’-hydroxycotinine (3HC) in saliva [12]. This
method is a validated measure of nicotine metabolism
[13,14]. The hepatic cytochrome CYP2A6 enzyme is re-
sponsible for the metabolism of nicotine, cotinine and
3HC, therefore NMR is a marker of CYP2A6 activity
[12,15], and a higher NMR (3HC/COT) indicates faster
nicotine metabolism.
Statistical analysis
Based on previous research we assumed a standard devia-
tion of 0.15 between time-points [16], and taking statistical
signiﬁcance as P<0.05, a sample size of 73 participants
would provide 80% power to detect a difference of 0.05
(1/3 of a standard deviation). NMR was not distributed
normally, and was log-transformed to normality. Levene’s
test was used to conﬁrm that there was no difference in
variance of NMR between time-points. The overall signiﬁ-
cance of the change in NMR between time-points was
assessed using a multi-level model, which allows us to
assess the signiﬁcance of a change over timewhile allowing
for the correlation between repeated measurements made
on individuals.
NMR was compared descriptively between each of the
ﬁve time-points: 8–14, 18–22 and 32–36weeks’ gestation
and 4 and 12weeks postpartum. Similar to previous re-
search, we used the 12-week postpartumNMRas the com-
parison value in this study [4] and a priori-determined
paired t-tests were performed to determine differences in
NMR at 12weeks postpartum and all other time-points.
The Bonferroni correction was used for multiple testing
in the four pairwise comparisons of each time-point with
the 12-week postpartum value [17], so P-values of 0.01
or smaller were signiﬁcant at the 5% level. We also
averaged all measurements made on an individual during
the antenatal period (8–14, 18–22 and 32–36weeks)
and the postpartum period (4 and 12weeks postpartum)
and compared these using a paired t-test to determine
the magnitude and statistical signiﬁcance of change in
NMR between the antenatal and postpartum periods. Effect
sizes are presented as percent change from the 12-week
postpartum result by anti-logging the mean difference.
We observed the 26womenwho returned all ﬁve saliva
samples and looked to see if the NMR followed a similar pat-
tern of NMR over time to that described using all available
samples, and then conducted multi-level analysis to test for
change over time within this subsample. Evidence suggests
the contraceptive pill increases nicotine metabolism
[18,19], so we excluded those who reported using contra-
ception at either 4 or 12weeks postpartum.
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RESULTS
Of 101 saliva samples provided at recruitment (8–
14weeks), 98 were able to be analysed (Fig. 1). The ﬁrst
follow-up at 18–22weeks’ gestation had the highest re-
turn rate (n=65, 64%) and the lowest response rate was
at 4weeks postpartum (sample n=44, 43%). The re-
sponse for the ﬁnal sample at 12weeks postpartum was
47 (46%). A total of 79 (78%) women provided more
than one sample for comparison and 26 (26%) women
provided a sample at all ﬁve time-points. The median
(IQR) number of cigarettes participants smoked at each
time-point was: 8–14weeks, 10 (5–10); 18–22weeks,
10 (4–11); 32–36weeks, 10 (5–10); 4weeks postpar-
tum, 10 (7.5–15); and 12weeks postpartum, 10
(7–15). Two participants who provided follow-up
samples reported to have used NRT.
The characteristics of the 101 participants recruited can
be seen in Table 1. We compared the characteristics of the
entire sample at recruitment with those of participants
who returned the 12-week postpartum sample (n=47).
There was a slight difference in the median number of
Figure 1 Recruitment and follow-up rates for samples and surveys
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cigarettes smoked. Also, only one of the ﬁve non-white eth-
nic participants returned a sample at 12weeks postpartum.
The remaining characteristics appeared similar between
the two groups. The mean of the log-transformed values
of NMR at different time-points is shown in Fig. 2. There
was a signiﬁcant difference in NMR over time (multi-level
model, P=0.0006). Nicotine metabolism appears higher
in pregnancy than outside pregnancy, and after pregnancy
the ratio appears to fall by 4weeks postpartum.
Table 2 shows the pairwise comparison of NMR at
12weeks postpartum with NMR at other time-points. After
accounting formultiple comparisons, NMRwas signiﬁcantly
higher at 18–22weeks (P=0.001) and 32–36weeks
(P=0.003) compared to NMR 12weeks postpartum.
There was no statistical difference between the samples
obtained at 8–14 weeks’ gestation or 4weeks postpartum
and 12weeks postpartum. The ‘within-participant’
Table 1 Characteristics of sample at recruitment and 12weeks postpartum.
Variables at recruitment
Recruitment: 8–14 weeks’
gestation (n= 101)
Returned sample/survey at
12weeks postpartum (n=47)
Maternal age (median, IQR) 24 (20–28) 25 (20–29)
Gestation at recruitment (mean and SD) 12.3 (1.78) 12.3 (1.77)
Cigarettes smoked at recruitment (median IQR) 10 (5–10) 8 (5–12)
Carbon monoxide reading (CO) 11 (7–16) 11 (8–16)
Employment (n, %)
Employed 32 32% 18 41%
Unemployed 34 34% 12 25%
Full-time student 3 3% 1 2%
Homemaker/parent 30 30% 14 29%
Other 2 2% 2 4%
Qualiﬁcations (n, %)
None 20 20% 9 18%
GCSE or equivalent 57 57% 24 53%
A levels/equivalent 19 19% 11 22%
Degree/equivalent 2 2% 1 2%
Other 3 3% 2 4%
Partner smokes (n, %)
Yes 71 70% 36 77%
No 19 19% 11 23%
No partner 11 11% – –
Partner/family smoke in home (n, %)
Yes 36 35% 18 50%
No 35 36% 18 50%
Ethnicity (n, %)
White British/Irish/other white 96 95% 46 98%
Other background 5 5% 1 2%
Fagerström categorical (n, %)
Mildly addicted< 4 56 55% 25 53%
Moderately addicted 4–6 37 36% 19 41%
Highly addicted 7–10 8 7% 3 6%
BMI categorical (8–14 weeks’ gestation) (n, %)
Underweight, less than 18.5 9 8% 3 7%
Healthy weight, 18.5–24.9 50 50% 21 46%
Overweight, 25–29.9 20 20% 10 22%
Obese, above 30 21 21% 12 26%
Missing 1 1% 1 2%
BMI = body mass index; GCSE = General Certiﬁcate of Secondary Education; IQR = interquartile range; SD = standard deviation.
Figure 2 Nicotine metabolite ratio (NMR) over time
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comparison of mean log-transformed NMR from samples
collected during pregnancy with those collected after
delivery (4 and 12weeks postpartum combined) showed
that NMR was 17% higher in the antenatal period
(95% CI =6–26%, P=0.023).
The analysis involving the 26 women who returned a
sample at every time-point showed a similar pattern of
NMR, and there remained a signiﬁcant change in NMR
over time (P=0.003). After excluding women who re-
ported using contraception at either 4 or 12weeks postpar-
tum (n=7) the pattern of NMRover time appeared similar,
and therewas still a signiﬁcant difference inNMRover time
(P=0.002).
DISCUSSION
To our knowledge, this is the ﬁrst study to describe the lon-
gitudinal pattern of nicotine metabolism from as early as
8weeks’ gestation until 12weeks following birth. Our
ﬁndings show that nicotine metabolism appears to be
faster in pregnancy; this faster metabolism is apparent
from 18 to 22weeks of pregnancy and appears to fall by
4weeks after childbirth
This study is one of the largest pharmacokinetic studies
of any drug throughout pregnancy [20,21]. From the
samewomen, we have been able to take repeatedmeasures
of NMR which enabled us to explore the within-subject
changes over time. To our knowledge, this is also the only
study to record nicotine metabolism accurately soon after
pregnancy (4weeks postpartum) and also at a much later
point following birth (12weeks postpartum), so our ﬁnding
that there was no further fall in nicotine metabolism
between 4 and 12weeks postpartum is a novel ﬁnding.
We used the 12weeks postpartum sample as our com-
parison sample. Ideally, the comparison NMR would have
been collected before conception and participants would
have been followed into pregnancy. However, recruiting
prior to conception would be difﬁcult, as most women
access health-care after ﬁnding out they are pregnant.
Our response rate fell to below 50% by the time of
the 4-week postpartum sample; this could have given
rise to response bias. However, we found no major
differences between women who returned the 12-week
postpartum sample and all women recruited to the co-
hort. We used a multi-level model which enabled us to
include all available data, but also conducted sensitivity
analysis on participants who provided a sample at every
time-point; this showed a similar pattern of nicotine me-
tabolism changes to that observed in the primary analy-
sis, again suggesting that response bias did not impact
unduly upon study results.
Consistent with a previous study, we have shown
that nicotine metabolism is faster during pregnancy
compared to the post-partum period [4]. Our study also
found that at 18–22 and 32–36weeks’ gestation NMR
was signiﬁcantly different from 12weeks postpartum.
The difference between 8–14 weeks’ gestation and
12weeks postpartum was in the same direction, but
was not signiﬁcant after allowing for multiple testing;
low statistical power may have contributed to this
ﬁnding. Studies which have been able to derive longitu-
dinal trends during pregnancy have relied upon the
analysis of hair samples which cannot provide measure-
ment at precise time-points, and may be problematic
due to contamination from hair products or passive
smoking [6,7].
Non-pregnant women who use contraceptives contain-
ing either progesterone or a combination of oestrogen and
progesterone hormones metabolize nicotine faster com-
pared to women not using contraception [18,19]. During
pregnancy these hormones begin to rise after conception,
and are increased markedly throughout pregnancy. It is
speculated that these hormones are responsible for the
increased CYP2A6 activity during pregnancy [15]. This
could explain why at 4weeks postpartum there was a
decline in NMR, as following birth there would be a rapid
reduction in these hormones. However, the exact causes
of increased nicotine metabolism require investigation.
We hypothesized originally that if nicotine metabolism
increased during pregnancy then the dose of nicotine in
NRT may not be enough to alleviate nicotine withdrawal
symptoms. As we have shown an increase in nicotine
metabolism during pregnancy, this suggests that higher
doses of NRT may be necessary. Observational evidence
has shown that, during pregnancy, using a combination
of long- and short-term-acting NRT (patch and a
Table 2 Pairwise comparisons of nicotine metabolism ratio (NMR) at 12weeks postpartum with each time-point antenatally and
postpartum
Comparison to 12weeks postpartum Percentage difference 95% conﬁdence intervals P-value
8–14 weeks’ gestation (46 paired samples) +15% +1% to +26% 0.034
18–22 weeks’ gestation (37 paired samples) +26% +12% to +38% 0.001*
32–36 weeks’ gestation (31 paired samples) +23% +9% to +35% 0.003*
4weeks postpartum (35 paired samples) +9% –12% to +26% 0.405
* P values < 0.125 are signiﬁcant.
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faster-acting form) is associated with higher short-term
quit rates compared with those attributable to using either
no medication or single form NRT [22]. However, to date
no randomized control trials have investigated this, so fur-
ther research is required on the effectiveness of higher-dose
NRT and combinations of patch plus a faster-acting form.
In conclusion, we have shown that in pregnancy nico-
tine metabolism is increased compared to the postpartum
period; it falls between birth and 1month and does not
seem to fall further after this.
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